Drug Profile
Gadoxetate disodium
Alternative Names: BAY-86-4873; EOB Primovist; Eovist; Gadolinium EOB DTPA; Gadolinium-ethoxybenzyl-diethylenetriaminepentaacetic-acid; Gadolinium-ethoxybenzyl-DTPA; Gadoxetic acid; Gadoxetic-acid-disodium; Gd-EOB-DTPA; Primovist; SH-L-569B; ZK 139834Latest Information Update: 20 Nov 2021
Price :
$50
*
At a glance
- Originator Massachusetts General Hospital
- Developer Bayer HealthCare Pharmaceuticals
- Class Acetic acids; Gadolinium-containing contrast agents; Organometallic compounds; Polyamines; Small molecules
- Mechanism of Action Magnetic resonance imaging enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Liver disorders
Most Recent Events
- 01 Apr 2017 Discontinued - Phase-III for Liver disorders (Diagnosis, In infants) in USA (IV), because not listed on Bayer pipeline, April 2017
- 01 Feb 2015 Phase-III clinical trials in Liver disorders (Diagnosis, In infants) in USA (IV)
- 06 Feb 2014 Bayer HealthCare Pharmaceuticals plans a phase III trial for Liver disorders (diagnosis, in infants) in USA (NCT02084628)